Advertisement

News

Make CHEST Physician® a trusted source
  • Psilocybin-assisted therapy bests nicotine patch for smoking cessation in pilot study

    Psilocybin-assisted therapy bests nicotine patch for smoking cessation in pilot study

    At six months following the target quit date, 40.5% of participants in the psilocybin group achieved biochemically verified prolonged abstinence compared with only 10.0% in the nicotine patch group.


  • Updated sepsis guidelines balance rapid treatment initiation, antibiotic stewardship

    Updated sepsis guidelines balance rapid treatment initiation, antibiotic stewardship

    In some cases, the new recommendations support treatment initiation before a patient reaches the hospital, while allowing flexibility in other cases to delay treatment until a sepsis diagnosis is confirmed.


  • Small trial shows lower ARDS rate, mortality with sivelestat following cardiopulmonary bypass

    Small trial shows lower ARDS rate, mortality with sivelestat following cardiopulmonary bypass

    Nicholas Villalobos, MD, said that while sivelestat may not represent a single solution for ARDS, evidence that it can temper the inflammatory cascade is positive.



  • Umeclidinium-vilanterol shows modest but consistent advantage among LAMA-LABA options in symptomatic COPD

    Umeclidinium-vilanterol shows modest but consistent advantage among LAMA-LABA options in symptomatic COPD

    Investigator William B. Feldman, MD, PhD, MPH, said the findings raise important questions about whether inhalers in the same class are indeed therapeutically equivalent for patients with COPD.


  • Triple therapy shows meaningful benefits in uncontrolled asthma

    Triple therapy shows meaningful benefits in uncontrolled asthma

    Alberto Papi, MD, FCCP, said recent data from the KALOS and LOGOS trials suggest triple therapy may address airflow limitation and exacerbation risk in a single inhaler.


  • Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF

    Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF

    Steven D. Nathan, MD, FCCP, said the evidence shows the drug is effective for treating pulmonary hypertension and may slow or prevent fibrosis progression.


  • Study supports early TB therapy to reduce sepsis mortality in HIV

    Study supports early TB therapy to reduce sepsis mortality in HIV

    The ATLAS team of researchers said that because typical sepsis treatment does not target TB, clinicians should consider immediate TB treatment for people with HIV-related sepsis.


  • Data show oral nalbuphine significantly reduces chronic cough in idiopathic pulmonary fibrosis

    Data show oral nalbuphine significantly reduces chronic cough in idiopathic pulmonary fibrosis

    Experts discuss the promising results—particularly surrounding patient-reported outcomes in this population—and the need for long-term safety data.



  • Large, longitudinal study adds to evidence that links OSA to mental health disorder

    Large, longitudinal study adds to evidence that links OSA to mental health disorder

    Colin Huntley, MD, said the data help to confirm what many have seen in the clinic and suggest that patients may see mental health improvements if their sleep apnea is better managed.


  • Study finds triple combination modulator therapy reduces inflammation in CF

    Study finds triple combination modulator therapy reduces inflammation in CF

    Valentino Bezzerri, PhD, discusses findings from a compassionate-use study examining the effects of elexacaftor/tezacaftor/ivacaftor on inflammation in patients with cystic fibrosis.